Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo

AIDS Research and Human Retroviruses

Volumn 27, Issue 3, 2011, Pages 295-302

  Tungsiripat, Marisa ^a   El Bejjani, Dalia ^b,c   Rizk, Nesrine ^c   Dogra, Vikram ^d   O'Riordan, Mary Ann ^c   Ross, Allison C ^c   Hileman, Corrilynn ^c   Storer, Norma ^c   Harrill, Danielle ^c   McComsey, Grace A ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; PROTEINASE INHIBITOR; ROSIGLITAZONE; THYMIDINE DERIVATIVE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; ANTIVIRAL THERAPY; ARTERIAL WALL THICKNESS; ARTERY ENDOTHELIUM; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; CAROTID ARTERY; CAROTID ATHEROSCLEROSIS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SUBSTITUTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INSULIN BLOOD LEVEL; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADULT; ANTI-RETROVIRAL AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID ARTERY, COMMON; CHOLESTEROL; CYTOKINES; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; EXTREMITIES; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION; LIPODYSTROPHY; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TUNICA INTIMA;

EID: 79952604958     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0187     Document Type: Article

References (32)

1. CDC: Deaths: Preliminary Data for 2001. Accessed on Oc-tober 29, 2004 at http://www.cdc.gov/nchs/data/nvsr/nvsr51/nvsr51-0f.pdf.
2. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al.: Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
3. Klein D, Hurley L, and Silverberg M: Surveillance data for myocardial infarctions hospitalizations among HIV+ and HIV-Northern Californians: 1994-2006. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 24-28, 2007. Abstract 807.
4. El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, et al.: Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: A randomized trial. Ann Intern Med 2008;149:289-299.
5. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dube MP, et al.: Endothelial function in human immuno-deficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008;52:569-576.
6. Ross AC, Armentrout R, O'Riordan MA, Storer N, Rizk N, Harrill D, et al.: Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr 2008;49:499-506.
7. Espeland MA, O'Leary D H, Terry JG, Morgan T, Evans G, and Mudra H: Carotid intimal-media thickness as a surro-gate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 2005;6:3.
8. Ogata T, Yasaka M, Yamagishi M, Seguchi O, Nagatsuka K, and Minematsu K: Atherosclerosis found on carotid ultra-sonography is associated with atherosclerosis on coronary intravascular ultrasonography. J Ultrasound Med 2005;24: 469-474. (Pubitemid 40470894)
9. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, et al.: Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003;289:1675-1680. (Pubitemid 37430273)
10. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, and Boerwinkle E: Circulating adhesion mol-ecules VCAM-1, ICAM-1, and E-selectin in carotid athero-sclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC) study. Circu-lation 1997;96:4219-4225. (Pubitemid 28007447)
11. Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, et al.: Serum myeloperoxidase levels inde-pendently predict endothelial dysfunction in humans. Cir-culation 2004;110:1134-1139. (Pubitemid 39319014)
12. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, and Fuchs D: Soluble receptors for tumour ne-crosis factor in clinical laboratory diagnosis. Eur J Haematol 1995;54:1-8.
13. McComsey GA, Smith K, Patel P, et al.: Similar reductions in markers of inflammation and endothelial activation after initiation of abacavir/lamivudine or tenofovir/emtricitabine: The HEAT Study. 16th Conference on Retro-viruses and Opportunistic Infections, February 8-11, 2009, Montreal, CA. Abstract 732.
14. Mulligan K, Yang Y, Wininger DA, Koletar SL, Parker RA, Alston-Smith BL, et al.: Effects of metformin and rosiglita-zone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS 2007;21:47-57. (Pubitemid 44912536)
15. Tungsiripat M, Bejjani DE, Rizk N, O'Riordan MA, Ross AC, Hileman C, et al.: Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS 2010; 24(9):1291-1298.
16. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, and Grinspoon S: Metabolic effects of rosiglitazone in HIV lipo-dystrophy: A randomized, controlled trial. Ann Intern Med 2004;140:786-794.
17. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, et al.: No effect of rosiglitazone for treatment of HIV-1 li-poatrophy: Randomised, double-blind, placebo-controlled trial. Lancet 2004;363:429-438. (Pubitemid 38210059)
18. Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, and Walmsley S: A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis 2007;195:1754-1761. (Pubitemid 46870247)
19. Gelato MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, Brathwaite CE, et al.: Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with ro-siglitazone: A pilot study. J Acquir Immune Defic Syndr 2002;31:163-170. (Pubitemid 35190570)
20. Sutinen J, Hakkinen AM, Westerbacka J, Seppala-Lindroos A, Vehkavaara S, Halavaara J, et al.: Rosiglitazone in the treatment of HAART-associated lipodystrophy\a random-ized double-blind placebo-controlled study. Antiviral Ther 2003;8:199-207 (Pubitemid 36960893)
21. Nissen SE and Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471. (Pubitemid 46919772)
22. Dormuth CR, Maclure M, Carney G, Schneeweiss S, Bassett K, and Wright JM: Rosiglitazone and myocardial infarction in patients previously prescribed metformin. PLoS One 2009;4:e6080.
23. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al.: Rosiglitazone evaluated for cardiovas-cular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet 2009;373:2125-2135.
24. Sidhu JS, Kaposzta Z, Markus HS, and Kaski JC: Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without dia-betes mellitus. Arterioscler Thromb Vasc Biol 2004;24:930-934. (Pubitemid 38620874)
25. Ryan KE, McCance DR, Powell L, McMahon R, and Trimble ER: Fenofibrate and pioglitazone improve endothelial func-tion and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 2007;194:e123-130. (Pubitemid 47513101)
26. El Bejjani D, Tungsiripat M, and Rizk N: Rosiglitazone im-proves lipoatrophy in patients receiving thymidine-sparing regimens. 16th Conference on Retroviruses and Opportu-nistic Infections, February 8-11, 2009, Montreal, CA. Abstract 42LB.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Trea-cher DF, and Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419. (Pubitemid 15018832)
28. Riley WA, Craven T, Romont A, and Furberg CD: Assess-ment of temporal bias in longitudinal measurements of ca-rotid intimal-medial thickness in the Asymptomatic Carotid Artery Progression Study (ACAPS). ACAPS Research Group. Ultrasound Med Biol 1996;22:405-411. (Pubitemid 26166932)
29. O'Leary DH, Polak JF, Wolfson SK, Jr., Bond MG, Bommer W, Sheth S, et al.: Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research Group. Stroke 1991; 22:1155-1163.
30. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, and Wolfson SK Jr: Carotid-artery intima and media thick-ness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-22. (Pubitemid 29024679)
31. Sakaguchi M, Kitagawa K, Nagai Y, Yamagami H, Kondo K, Matsushita K, et al.: Equivalence of plaque score and intima-media thickness of carotid ultrasonography for predicting severe coronary artery lesion. Ultrasound Med Biol 2003; 29:367-371. (Pubitemid 36434324)
32. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, and Waters DD: Progression of atherosclerosis as as-sessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004;109:1603-1608. (Pubitemid 38451715)